Immunogen (IMGN) to Release Earnings on Friday
Immunogen (NASDAQ:IMGN) will be posting its Q314 quarterly earnings results on Friday, April 25th. Analysts expect Immunogen to post earnings of ($0.27) per share and revenue of $13.28 million for the quarter.
Immunogen (NASDAQ:IMGN) last posted its quarterly earnings results on Friday, January 31st. The company reported ($0.29) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.11. The company had revenue of $30.10 million for the quarter, compared to the consensus estimate of $18.16 million. During the same quarter last year, the company posted ($0.29) earnings per share. Immunogen’s revenue was up 1057.7% compared to the same quarter last year. On average, analysts expect Immunogen to post $-0.67 EPS for the current fiscal year and $-0.93 EPS for the next fiscal year.
Immunogen (NASDAQ:IMGN) opened at 13.90 on Thursday. Immunogen has a 52-week low of $11.78 and a 52-week high of $20.25. The stock has a 50-day moving average of $14.96 and a 200-day moving average of $15.31. The company’s market cap is $1.191 billion.
IMGN has been the subject of a number of recent research reports. Analysts at Canaccord Genuity initiated coverage on shares of Immunogen in a research note on Wednesday, April 16th. They set a “buy” rating and a $20.00 price target on the stock. On a related note, analysts at Zacks upgraded shares of Immunogen from a “neutral” rating to an “outperform” rating in a research note on Monday, April 7th. They now have a $15.90 price target on the stock. Finally, analysts at Guggenheim raised their price target on shares of Immunogen from $14.00 to $15.00 in a research note on Friday, January 31st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $17.78.
ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.